CD8A and metastatic neoplasm: Similarly, our phase I-II clinical trial of SBRT plus ipilimumab in patients with metastatic tumors in lung or liver, partial response or stable disease (≥6 months) was associated with a higher number of peripheral CD8+ T-cells, higher CD8+/CD4+ ratios, and an increased number of either activated (4-1BB expressing) or potentially exhausted (PD1 expressing) CD8+ T-cells (62).